Thats according to a small clinical trial run by Novo Nordisk, so real-life results may vary
The bad news is that for the foreseeable future, consumers will continue to pay high prices, and employers are likely to continue to be more circumspect about coverage
Conducting rigorous studies like those that established the benefits of injectable GLP-1 RAs such as tirzepatide, semaglutide, dulaglutide, and liraglutide on CKD, MASH, and cardiovascular outcomes will be crucial in determining the full clinical utility of these novel agents
This synthetic version of the natural hormone glucagon-like peptide-1 (GLP-1) has the dual advantage of regulating blood sugar levels and promoting weight loss
NICE recommends prescribing semaglutide 2.4 mg with dietary and physical activity support for adults with weight-related complications (i.e., cardiovascular disease) and BMI 35 kg/m 2 (or exceptionally 30) within specialist services [5]